1. Home
  2. TKNO vs SGMT Comparison

TKNO vs SGMT Comparison

Compare TKNO & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TKNO
  • SGMT
  • Stock Information
  • Founded
  • TKNO 1996
  • SGMT 2006
  • Country
  • TKNO United States
  • SGMT United States
  • Employees
  • TKNO N/A
  • SGMT N/A
  • Industry
  • TKNO Medicinal Chemicals and Botanical Products
  • SGMT
  • Sector
  • TKNO Health Care
  • SGMT
  • Exchange
  • TKNO Nasdaq
  • SGMT Nasdaq
  • Market Cap
  • TKNO 256.9M
  • SGMT 230.3M
  • IPO Year
  • TKNO 2021
  • SGMT 2023
  • Fundamental
  • Price
  • TKNO $4.35
  • SGMT $7.51
  • Analyst Decision
  • TKNO
  • SGMT Strong Buy
  • Analyst Count
  • TKNO 0
  • SGMT 7
  • Target Price
  • TKNO N/A
  • SGMT $26.57
  • AVG Volume (30 Days)
  • TKNO 221.4K
  • SGMT 635.5K
  • Earning Date
  • TKNO 08-07-2025
  • SGMT 08-13-2025
  • Dividend Yield
  • TKNO N/A
  • SGMT N/A
  • EPS Growth
  • TKNO N/A
  • SGMT N/A
  • EPS
  • TKNO N/A
  • SGMT N/A
  • Revenue
  • TKNO $38,923,000.00
  • SGMT N/A
  • Revenue This Year
  • TKNO $9.52
  • SGMT N/A
  • Revenue Next Year
  • TKNO $15.20
  • SGMT N/A
  • P/E Ratio
  • TKNO N/A
  • SGMT N/A
  • Revenue Growth
  • TKNO 11.40
  • SGMT N/A
  • 52 Week Low
  • TKNO $4.00
  • SGMT $1.73
  • 52 Week High
  • TKNO $10.37
  • SGMT $11.41
  • Technical
  • Relative Strength Index (RSI)
  • TKNO 43.35
  • SGMT 43.71
  • Support Level
  • TKNO $4.22
  • SGMT $6.97
  • Resistance Level
  • TKNO $4.94
  • SGMT $7.86
  • Average True Range (ATR)
  • TKNO 0.29
  • SGMT 0.63
  • MACD
  • TKNO -0.00
  • SGMT -0.06
  • Stochastic Oscillator
  • TKNO 16.75
  • SGMT 27.71

About TKNO Alpha Teknova Inc.

Alpha Teknova Inc provides critical reagents that enable the discovery, development, and production of biopharmaceutical products such as drug therapies, novel vaccines, and molecular diagnostics. Its offer three product types: pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It derives key revenue from United States.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: